» Articles » PMID: 10449618

Nasopharyngeal Carcinoma Cell Line (C666-1) Consistently Harbouring Epstein-Barr Virus

Overview
Journal Int J Cancer
Specialty Oncology
Date 1999 Aug 17
PMID 10449618
Citations 187
Authors
Affiliations
Soon will be listed here.
Abstract

We have established a cell line (C666-1) from undifferentiated nasopharyngeal carcinoma (NPC). This cell line consistently carries the Epstein-Barr virus (EBV) in long-term cultures. C666-1 is a subclone of its parental cell line, C666, derived from an NPC xenograft of southern Chinese origin. It grows as an adherent culture and lacks contact inhibition. In addition, it is tumorigenic in athymic nude mice. The cells consistently express EBV-encoded RNAs and are positively stained for cytokeratin, an epithelial marker. In addition, they express EBNA1 protein, LMP1 and LMP2 transcripts and thus resemble the EBV latency II pattern. The virus genotype is EBV-1 with the latent membrane protein 1 gene showing a 30-bp deletion at the carboxyl terminus, both consistent with findings in southern Chinese NPC tumours. Cytogenetic analysis revealed a sub-diploid status with a chromosomal modal number of 45. C666-1 is unique among NPC cell lines in that it carries EBV. These cells may serve as a good investigative tool as the viral latency pattern and genotype are observed in the majority of primary NPC biopsies from Chinese patients.

Citing Articles

Genetic Characterization of the Immortalized Human Nasopharyngeal Carcinoma Cell Line NPC/HK1.

Makowska A, Kontny U, van Helden J, Hildebrandt B, Schuler H, Weiskirchen R Cancer Med. 2025; 14(3):e70422.

PMID: 39905741 PMC: 11794828. DOI: 10.1002/cam4.70422.


EBV-induced upregulation of CD55 reduces the efficacy of cetuximab treatment in nasopharyngeal carcinoma.

Zhu Q, Duan X, Hu H, You R, Xia T, Yu T J Transl Med. 2024; 22(1):1111.

PMID: 39695702 PMC: 11653747. DOI: 10.1186/s12967-024-05822-3.


Establishment of a visualized mouse orthotopic xenograft model of nasopharyngeal carcinoma.

Chen W, Chen W, Chen S, Jiang L, Shu G, Yin Y Cancer Biol Ther. 2024; 25(1):2382531.

PMID: 39206791 PMC: 11364074. DOI: 10.1080/15384047.2024.2382531.


Development of [Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma.

Chen J, Pang Y, Liao X, Zhou Y, Luo Q, Wu H Eur J Nucl Med Mol Imaging. 2024; 52(1):247-259.

PMID: 39145784 DOI: 10.1007/s00259-024-06874-9.


Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers.

Wu M, Hau P, Li L, Tsang C, Yang Y, Taghbalout A Nat Commun. 2024; 15(1):3729.

PMID: 38702330 PMC: 11068728. DOI: 10.1038/s41467-024-48031-8.